Your session is about to expire
← Back to Search
Monoclonal Antibodies
Atezolizumab + Bevacizumab for Endometrial Cancer
Phase 2
Recruiting
Led By Kathleen Moore, MD
Research Sponsored by University of Oklahoma
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Evidence that the endometrial cancer is advanced, recurrent, or persistent and has relapsed or is refractory to curative therapy or established treatments
Patients MSI status must be known (via immunohistochemistry)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
Study Summary
This trial will test the safety and effectiveness of a combination of two drugs, atezolizumab and bevicacizumab, in women with endometrial cancer that has progressed or come back after treatment.
Who is the study for?
This trial is for women with advanced, recurrent or persistent endometrial cancer who have tried at least one platinum-based chemotherapy but no more than two regimens. Participants must be over 18, understand the study and consent to it, have measurable disease by certain medical imaging standards, an ECOG performance status of 0-2, and agree to use contraception if of childbearing potential.Check my eligibility
What is being tested?
The trial is testing a combination of two drugs: Atezolizumab and Bevacizumab in women with specific types of endometrial cancer. It's a Phase II study focusing on the safety and effectiveness (futility) of this drug combo without comparing it to other treatments.See study design
What are the potential side effects?
Potential side effects include allergic reactions related to antibodies or proteins in the drugs; risk of infection; possible nerve damage; gastrointestinal issues like fistula or perforation; bleeding disorders; severe fatigue; and complications from immune system interactions.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My endometrial cancer is advanced, recurrent, or persistent and does not respond to standard treatments.
Select...
My cancer's MSI status has been tested.
Select...
I have a tumor or lymph node that meets the size requirements for measurement.
Select...
My cancer is a type of endometrial carcinoma.
Select...
I have had 1 or 2 platinum-based treatments for endometrial cancer.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of patients who experience complete or partial tumor response
Secondary outcome measures
Number of participants who experience immune related response
Number of patients who experience toxicity
Overall survival
+1 moreTrial Design
1Treatment groups
Experimental Treatment
Group I: Bevacizumab + AtezolizumabExperimental Treatment2 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Bevacizumab
2013
Completed Phase 4
~5280
Atezolizumab
2017
Completed Phase 3
~5860
Find a Location
Who is running the clinical trial?
University of OklahomaLead Sponsor
455 Previous Clinical Trials
97,500 Total Patients Enrolled
6 Trials studying Endometrial Cancer
231 Patients Enrolled for Endometrial Cancer
Genentech, Inc.Industry Sponsor
1,540 Previous Clinical Trials
567,789 Total Patients Enrolled
6 Trials studying Endometrial Cancer
356 Patients Enrolled for Endometrial Cancer
Kathleen Moore, MDPrincipal InvestigatorObstetrics and Gynecology
8 Previous Clinical Trials
335 Total Patients Enrolled
2 Trials studying Endometrial Cancer
88 Patients Enrolled for Endometrial Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I started taking corticosteroids not more than a week ago.I have brain metastases but meet specific treatment criteria.I am HIV positive but not immunocompromised, or I am on antiretroviral therapy.I haven't had serious abdominal issues, wounds, or fractures in the last 6 months.I have moderate to severe numbness, tingling, or muscle weakness.I do not have any severe health issues that could affect my participation in the study.My endometrial cancer is advanced, recurrent, or persistent and does not respond to standard treatments.I understand and agree to sign the Informed Consent Form for the study.My cancer's MSI status has been tested.I have been treated with anti-PD-1 or anti-PD-L1 therapy.I have an autoimmune disorder like SLE, sarcoidosis, RA, or Crohn's.I have a tumor or lymph node that meets the size requirements for measurement.I haven't had any cancer besides non-melanoma skin cancer or carcinoma in situ, or if I did, it was more than 2 years ago and fully treated.I haven't taken any immune-boosting drugs in the last 6 weeks.I can provide previous cancer tissue samples or agree to a new biopsy.I haven't had certain cancer treatments or recovered from their side effects in the last 4-6 weeks.I haven't had major surgery in the last 28 days and don't expect to need one during the study.My cancer is a type of endometrial carcinoma.I have had 1 or 2 platinum-based treatments for endometrial cancer.I am not pregnant or breastfeeding.I am a woman aged 18 or older.I can take care of myself and am up and about more than half of my waking hours.
Research Study Groups:
This trial has the following groups:- Group 1: Bevacizumab + Atezolizumab
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the aggregate number of individuals involved in this medical research?
"This research initiative is currently not recruiting; it was initially published 8/8/2018 and the information posted was last modified 11/21/2022. For those looking for alternative studies, there are 285 endometrial cancer trials and 621 trials using Bevacizumab taking on patients."
Answered by AI
What potential health risks accompany Bevacizumab treatment?
"There is some evidence of Bevacizumab's safety, so it was given a rating of 2. Unfortunately, there are no studies to suggest its efficacy as yet."
Answered by AI
To what illnesses is Bevacizumab commonly prescribed?
"Bevacizumab is a popular treatment for non-small cell lung carcinoma. Furthermore, this medication can be employed in the aftercare of surgeries for recurrent non-squamous NSCLC as well as to manage platinum-sensitive epithelial ovarian cancer."
Answered by AI
Are there still openings available in this experiment for participants?
"This medical study is not currently seeking patients. Initially posted on August 8th 2018 and most recently updated November 21st 2022, applicants are encouraged to explore the 285 clinical trials recruiting for endometrial cancer or 621 examining Bevacizumab's efficacy."
Answered by AI
Are there other experiential reports that focus on Bevacizumab?
"Bevacizumab was initially studied in 2004 at Memorial Sloan Kettering Basking Ridge. Since then, 1078 studies have been completed with 621 still ongoing; many of these tests are being administered from Oklahoma City, Oklahoma."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger